Home › Funds › JACOBS LEVY EQUITY MANAGEMENT, INC › WST

JACOBS LEVY EQUITY MANAGEMENT, INC position in WST

WEST PHARMACEUTICAL SVSC INC · Health Care

JACOBS LEVY EQUITY MANAGEMENT, INC reported holding 507,786 shares of WST (WEST PHARMACEUTICAL SVSC INC) in its Q2 2026 13F filing — a position valued at US$182.3M, representing 0.66% of its reported portfolio and ranking #28 among its reported holdings. JACOBS LEVY EQUITY MANAGEMENT, INC has disclosed WST holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)507.79K sh
Reported value held$182.30M
Portfolio Weight0.66%
First reportedQ1 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How JACOBS LEVY EQUITY MANAGEMENT, INC's WST position evolved

JACOBS LEVY EQUITY MANAGEMENT, INC first disclosed a stake in WST in Q1 2025 at 68,411 shares (US$15.3M). The position peaked in Q2 2026 at 507,786 shares, worth US$182.3M. Across 6 filings, JACOBS LEVY EQUITY MANAGEMENT, INC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 507,786 shares valued at US$182.3M — a reduction of -197,550 shares quarter over quarter.. Notable position changes include a 410% increase in Q2 2025 (shares rose 20% over the following quarter), a 56% increase in Q4 2025 (shares fell 9% over the following quarter), a 28% trim in Q2 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 68.41K $15.32M New
Q2 2025 349.22K $76.41M Add
Q3 2025 409.65K $107.46M Add
Q4 2025 639.56K $175.97M Add
Q1 2026 705.34K $176.79M Add
Q2 2026 507.79K $182.30M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About WST and 13F data

WST (WEST PHARMACEUTICAL SVSC INC) is a Health Care company. 34 other funds we track also report a position in WST — the largest reported positions include Artisan Partners Limited Partnership (US$865.8M), GENERATION INVESTMENT MANAGEMENT LLP (US$728.2M), BROWN ADVISORY INC (US$386.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding WST

All WST fund holders →

FAQ

How long has JACOBS LEVY EQUITY MANAGEMENT, INC held WST?

JACOBS LEVY EQUITY MANAGEMENT, INC has disclosed WST holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is JACOBS LEVY EQUITY MANAGEMENT, INC's current position in WST?

As of Q2 2026, JACOBS LEVY EQUITY MANAGEMENT, INC holds 507.79K shares of WST (WEST PHARMACEUTICAL SVSC INC), valued at $182.30M, representing 0.66% of its reported portfolio and ranking #28.

Has JACOBS LEVY EQUITY MANAGEMENT, INC been buying or selling WST?

In the latest 13F filing (Q2 2026), JACOBS LEVY EQUITY MANAGEMENT, INC reduced its position in WST. The position peaked in Q2 2026 at 507.79K shares.

Which other funds hold WST?

Other major institutional holders of WST include Artisan Partners Limited Partnership, GENERATION INVESTMENT MANAGEMENT LLP, BROWN ADVISORY INC, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.